HC Wainwright & Co. reiterated coverage on Protalix BioTherapeutics with a new price target

5/3/21 7:36:38 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

HC Wainwright & Co. reiterated coverage of Protalix BioTherapeutics with a rating of Buy and set a new price target of $7.00 from $11.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PLX

Date	Price Target	Rating	Analyst